Supported Employment COVID-19 Rapid Testing for PWID

April 7, 2026 updated by: University of Oregon

Supported Employment to Create a Community Culture of COVID-19 Rapid Testing Among People Who Inject Drugs: PeerConnect2Test

This community-engaged project aims to improve the accessibility of rapid tests through a supported employment program for people who inject drugs (PWID). The overall goal is to develop a transformative community-driven intervention in partnership with a community partner to promote widespread access to rapid testing among PWID.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The program is called Peer Connect2Test (PeerC2T). PWID will be recruited by a community partner who provides syringe exchange services. The community partner will train PWID to become peer health workers (PHW) to distribute SARS-CoV-2 rapid tests to other PWID. Investigators expect that PeerC2T will improve knowledge, self-efficacy, and health behaviors among PHWs.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
102

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Oregon
      • Eugene, Oregon, United States, 97403
        • University of Oregon

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 18 and older
  • Able to speak and understand English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Supported Employment for Peer Health Workers
Supported employment program (Peer Connect2Test) for people who inject drugs to provide SARS-CoV-2 rapid tests to others in their networks
Behavioral: Supported Employment
PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Workers to facilitate the distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated.
Other Names:
  • Peer Connect2Test

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Participant Peer Well-Being (Flourishing Scale)
Time Frame: Assessed at baseline and 3-month follow-up
Participant well-being was computed as the mean of eight items with a 7-point response option (1 = strongly disagree, 7 = strongly agree). The internal consistency, as measured with Cronbach's alpha (α), was .90, scores could range from 1 to 7, and higher scores indicated greater levels of well-being.
Assessed at baseline and 3-month follow-up

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Health Communication Self-Efficacy
Time Frame: Assessed at baseline and 3-month follow-up
Health communication self-efficacy was computed as the mean score of 14 items with a 5-point response option (1 = strongly disagree, 5 = strongly agree). The internal consistency, as measured with Cronbach's alpha (α), was .97; scores could range from 1 to 5, and higher scores indicated greater self-efficacy.
Assessed at baseline and 3-month follow-up
Peer Support Self-Efficacy
Time Frame: Assessed at baseline and 3-month follow-up
Peer support self-efficacy, an Aim 1 measure, was computed as the mean score of 18 items with a 5-point response option (1 = not at all confident, 5 = very confident). The internal consistency, as measured with Cronbach's alpha (α), was .96; scores could range from 1 to 5, and higher scores indicated greater self-efficacy.
Assessed at baseline and 3-month follow-up
COVID-19 Knowledge
Time Frame: Assessed at baseline and 3-month follow-up
COVID-19 knowledge was computed as the number of correctly endorsed items. Five items were presented to test knowledge of COVID-19. Scores could range from 0 to 5, and higher scores indicate greater levels of COVID-19 knowledge.
Assessed at baseline and 3-month follow-up
HIV Knowledge
Time Frame: Assessed at baseline and 3-month follow-up
HIV knowledge was computed as the number of correctly endorsed items. Four items were presented to test understanding of HIV. Scores could range from 0 to 4, and higher scores indicate greater levels of HIV knowledge.
Assessed at baseline and 3-month follow-up
Hepatitis C Knowledge
Time Frame: Assessed at baseline and 3-month follow-up
Hepatitis C knowledge was computed as the number of correctly endorsed items. Five items were presented to test understanding of HIV. Scores could range from 0 to 5, and higher scores indicate greater levels of hepatitis C knowledge.
Assessed at baseline and 3-month follow-up
Syphilis Knowledge
Time Frame: Assessed at baseline and 3-month follow-up
Syphilis knowledge was computed as the number of correctly endorsed items. Five items were presented to test understanding of HIV. Scores could range from 0 to 5, and higher scores indicate greater levels of Syphilis knowledge.
Assessed at baseline and 3-month follow-up
Naloxone Knowledge
Time Frame: Assessed at baseline and 3-month follow-up
Naloxone knowledge was computed as the number of correctly endorsed items. Five items were presented to test understanding of HIV. Scores could range from 0 to 5, and higher scores indicate greater levels of naloxone knowledge.
Assessed at baseline and 3-month follow-up
Harm Reduction Risk Behaviors - Number of Times a Person Injected Drugs
Time Frame: Assessed at baseline and 3-month follow-up
Harm reduction risk behaviors included behaviors that occurred in the past month, and a higher score indicated greater levels of risky behavior. The injected drugs score was the total number of times a person reported they had injected drugs.
Assessed at baseline and 3-month follow-up
Harm Reduction Risk Behaviors - Number of Times a Person Used Needles
Time Frame: Assessed at baseline and 3-month follow-up
Harm reduction risk behaviors included behaviors that occurred in the past month. The needle use score was a count of number of times they used a needle after someone else had used it (0 = none, 5 = more than 10 times), number of different people who used a needle before they had (0 = none, 5 = more than 10 times), number of times someone used a needle after they had (0 = none, 5 = more than 10 times), and before using needles how often they used bleach to clean the needles (0 = don't reuse, 5 = never). Scores could range from 0 to 20, and a higher score indicated a greater level of needle risky behaviors.
Assessed at baseline and 3-month follow-up
Harm Reduction Risk Behaviors - Number of Times Person Engaged in Risky Intercourse Behaviors
Time Frame: Assessed at baseline and 3-month follow-up
Harm reduction risk behaviors included behaviors that occurred in the past month. The intercourse score was a count of the number of people a person had sex within the last month (0 = none, 5 = more than 10 people), the number of times a person used condoms when having sex with regular partner(s) in the last month (0 = no regular partner, 6 = never), how often they used condoms when they paid for sex (0 = not paid sex, 5 = never), how often they used condoms when having sex with casual partners (0 = no casual partners, 5 = never), and how many times they had anal sex in the last month (0 = 0 times, 5 = more than 5 times). Scores could range from 0 to 26, and a higher score indicated a greater level of intercourse risky behaviors.
Assessed at baseline and 3-month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Oregon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 3, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 15, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 15, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 28, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 8, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 9, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 7, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • STUDY00000657

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We have shared data with the RADx-UP Data Coordination Center at Duke University. Data was de-identified and is available to other researchers for further use.

IPD Sharing Time Frame

Upon study completion. Timeframe available determined by the National Institutes of Health.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings